Actions of delta-9-tetrahydrocannabinol in cannabis: Relation to use, abuse, dependence

References

• Ator NA, Griffiths RR. Principles of drug abuse liability assessment in laboratory animals. Drug & Alcohol Dependence 2003; 70(Suppl.3)S55–72
   PubMed Web of Science ®Google Scholar
• Bardo MT, Bevins RA. Conditioned place preference: What does it add to our preclinical understanding of drug reward?. Psychopharmacology 2000; 153: 31–43
   PubMed Web of Science ®Google Scholar
• Bauman A, Phongsavan P. Epidemiology of substance use in adolescence: Prevalence, trends, and policy implications. Drug & Alcohol Dependence 1999; 55: 187–207
   PubMed Web of Science ®Google Scholar
• Benowitz NL, Jones RT. Cardiovascular and metabolic considerations in prolonged cannabinoid administration in man. Journal of Clinical Pharmacology 1981; 21: 214S–223S
   Google Scholar
• Bortolato M, Campolongo P, Mangieri RA, Scattoni ML, Frau R, Trezza V, et al. Anxioloytic-like properties of the anandamide transport inhibitor AM404. Neuropsychopharmacology 2006; 31: 2652–2659
   PubMed Web of Science ®Google Scholar
• Braida D, Pozzi M, Cavallini R, Sala M. Conditioned place preference induced by the cannabinoid agonist CP 55,940: Interaction with the opioid system. Neuroscience 2001; 104: 923–926
   PubMed Web of Science ®Google Scholar
• Braida D, Iosue S, Pegorini S, Sala M. Delta9-tetrahydrocannabinol-induced conditioned place preference and introcerebroventricular self-administration in rats. European Journal of Pharmacology 2004; 506: 63–69
   PubMedGoogle Scholar
• Budney AJ, Novy PL, Hughes JR. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999; 94: 1311–1321
   PubMed Web of Science ®Google Scholar
• Budney AJ, Hughes JR, Moore BA, Vandrey R. Review of the validity and significance of cannabis withdrawal syndrome. American Journal of Psychiatry 2004; 161: 1967–1977
   PubMed Web of Science ®Google Scholar
• Budney AJ, Hughes JR, Moore BA, Novy PL. Marijuana abstinence effects in marijuana smokers maintained in their home environment. Arch Gen Psychiatry 2001; 58: 917–924
   PubMed Web of Science ®Google Scholar
• Budney AJ, Vandrey RG, Hughes JR, Moore BA, Bahrenburg B. Oral delta-9-tetrahydrocannabinol suppresses cannabis withdrawal symptoms. Drug & Alcohol Dependence 2007; 86: 22–29
   PubMed Web of Science ®Google Scholar
• Carney JM, Uwaydah IM, Balster RL. Evaluation of a suspension system for intravenous self-administration of water insoluble substances in the rhesus monkey. Pharmacology Biochemistry and Behaviour 1977; 7: 357–364
   PubMedGoogle Scholar
• Castañé A, Robledo P, Matifas A, Kieffer BL, Maldonado R. Cannabinoid withdrawal syndrome is reduced in double mu and delta opioid receptor knockout mice. European Journal of Neuroscience 2003; 17: 155–159
   PubMed Web of Science ®Google Scholar
• Chait LD, Zacny JP. Reinforcing and subjective effects of oral delta 9-THC and smoked marijuana in humans. Psychopharmacology 1992; 107: 255–262
   PubMed Web of Science ®Google Scholar
• Chaperon F, Soubrie P, Puech J, Thiebot MH. Involvement of central cannabinoid (CB1) receptors in the establishment of place conditioning in rats. Psychopharmacology 1998; 135: 324–332
   PubMed Web of Science ®Google Scholar
• Cheer JF, Kendall DA, Marsden CA. Cannabinoid receptors and reward in the rat: A conditioned place preference study. Psychopharmacology 2000; 151: 25–30
   PubMed Web of Science ®Google Scholar
• Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS. Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. Journal of the American Medical Association 2004; 291: 2114–2121
   PubMed Web of Science ®Google Scholar
• Cooper ZD, Haney M. Comparison of subjective, pharmacokinetic, and physiologic effects of cannabis smoked as joints and blunts. Drug & Alcohol Dependence in press
   Google Scholar
• Deiana S, Fattore L, Spano MS, Cossu G, Porcu E, Fadda P, et al. Strain and schedule-dependent differences in the acquisition, maintenance and extinction of intravenous cannabinoid self-administration in rats. Neuropsychopharmacology 2007; 52: 646–654
   Google Scholar
• Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, et al. Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 2006; 17: 1629–1632
   PubMed Web of Science ®Google Scholar
• Fattore L, Cossu G, Martellotta CM, Fratta W. Intravenous self–administration of the cannabinoid CB1 receptor agonist WIN 55,212-2 in rats. Psychopharmacology 2001; 156: 410–416
   PubMed Web of Science ®Google Scholar
• Fattore L, Spano MS, Altea S, Angius F, Fadda P, Fratta W. Cannabinoid self-administration in rats: Sex differences and the influence of ovarian function. British Journal of Pharmacology 2007; 152: 795–804
   PubMed Web of Science ®Google Scholar
• Felder CC, Glass M. Cannabinoid receptors and their endogenous agonists. Annual Review of Pharmacology and Toxicology 1998; 38: 179–200
   PubMed Web of Science ®Google Scholar
• Fredericks AB, Benowitz NL. An abstinence syndrome following chronic administration of delta-9-tetrahydrocannabinol in rhesus monkeys. Psychopharmacology 1980; 71: 201–202
   PubMed Web of Science ®Google Scholar
• Gardner EL, Vorel SR. Cannabinoid transmission and reward-related events. Neurobiology of Disease 1998; 5(6 Pt B)502–533
   PubMed Web of Science ®Google Scholar
• Georgotas A, Zeidenberg P. Observations on the effects of four weeks of heavy marijuana smoking on group interaction and individual behavior. Comprehensive Psychiatry 1979; 20: 427–432
   PubMed Web of Science ®Google Scholar
• Haney M. Effects of smoked marijuana in healthy and HIV+ cannabis smokers. Journal of Clinical Pharmacology 2002; 42: 34S–40S
   PubMed Web of Science ®Google Scholar
• Haney M. The marijuana withdrawal syndrome: Diagnosis and treatment. Current Psychiatry Reports 2005; 7: 360–366
   PubMedGoogle Scholar
• Haney M. Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 2007; 32: 1391–1403
   PubMedGoogle Scholar
• Haney M. Self-administration of cocaine, cannabis and heroin in the human laboratory: Benefits and pitfalls. Addiction Biology 2008; 14: 9–21
   PubMedGoogle Scholar
• Haney M, Bisaga A, Foltin RW. Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology 2003; 166: 77–85
   PubMed Web of Science ®Google Scholar
• Haney M, Comer SD, Ward AS, Foltin RW, Fischman MW. Factors influencing marijuana self-administration by humans. Behavioral Pharmacology 1997; 8: 101–112
   PubMedGoogle Scholar
• Haney M, Hart CL, Vosburg SK, Nasser J, Bennett A, Zubaran C, et al. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology 2004; 29: 158–170
   PubMed Web of Science ®Google Scholar
• Haney M, Hart CL, Ward AS, Foltin RW. Nefazodone decreases anxiety during marijuana withdrawal in humans. Psychopharmacology 2003; 165: 157–165
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following oral THC administration to humans. Psychopharmacology 1999a; 141: 385–394
   PubMed Web of Science ®Google Scholar
• Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW. Abstinence symptoms following smoked marijuana in humans. Psychopharmacology 1999b; 141: 395–404
   PubMed Web of Science ®Google Scholar
• Harris RT, Waters W, McLendon D. Evaluation of reinforcing capability of Δ9-tetrahydrocannabinol in monkeys. Psychopharmacologia 1974; 37: 23–29
   PubMedGoogle Scholar
• Hart CL, Haney M, Vosburg SK, Comer SD, Foltin RW. Reinforcing effects of oral Δ9-THC in male marijuana smokers in a laboratory choice procedure. Psychopharmacology 2005; 181: 237–243
   PubMed Web of Science ®Google Scholar
• Hart CL, Haney M, Ward AS, Fischman MW, Foltin RW. Effects of oral THC maintenance on smoked marijuana self-administration. Drug & Alcohol Dependence 2002a; 67: 301–309
   PubMed Web of Science ®Google Scholar
• Hart CL, van Gorp WG, Haney M, Foltin RW, Fischman MW. Effects of acute smoked marijuana on complex cognitive performance. Neuropsychopharmacology 2001; 29: 158–170
   Google Scholar
• Hart CL, Ward AS, Haney M, Comer SD, Foltin RW, Fischman MW. Comparison of smoked marijuana and oral Δ9-tetrahydrocannabinol in humans. Psychopharmacology 2002b; 164: 407–415
   PubMed Web of Science ®Google Scholar
• Hirschhorn ID, Rosecrans JA. Morphine and delta 9-tetrahydrocannabinol: Tolerance to the stimulus effects. Psychopharmacologia 1974; 36: 243–253
   PubMedGoogle Scholar
• Huestis MA, Boyd SJ, Heischman SJ, Preston KL, Bonnet D, Le Fur G, et al. Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 2007; 194: 505–15
   PubMed Web of Science ®Google Scholar
• Huestis MA, Gorelick DA, Heishman SJ, Preston KL, Nelson RA, Moolchan ET, et al. Blockade of effects of smoked marijuana by the CB1-selective cannabinoid receptor antagonist SR141716. Archives of General Psychiatry 2001; 58: 322–328
   PubMed Web of Science ®Google Scholar
• Hutcheson DM, Tzavara ET, Smadja C, Valjent E, Roques BP, Hanoune J, et al. Behavioral and biochemical evidence for signs of abstinence in mice chronically treated with delta-9-tetrahydrocannabinol. British Journal of Pharmacology 1998; 125: 1567–1577
   PubMed Web of Science ®Google Scholar
• Jarbe TU, Lamb RJ, Lin S, Makriyannis A. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: Tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology 2001; 156: 369–380
   PubMedGoogle Scholar
• Jarbe TU, Liu Q, Makriyannis A. Antagonism of discriminative stimulus effects of Δ9-THC and (R)-methanandamide in rats. Psychopharmacology 2006; 184: 36–45
   PubMedGoogle Scholar
• Jones RT, Benowitz N, Bachman J. Clinical studies of cannabis tolerance and dependence. Annals of the New York Academy of Science 1976; 282: 221–239
   PubMed Web of Science ®Google Scholar
• Jones RT, Benowitz N, Herning RI. Clinical relevance of cannabis tolerance and dependence. Journal of Clinical Pharmacology 1981; 21: 143S–152S
   PubMed Web of Science ®Google Scholar
• Justinova Z, Tanda G, Munzar P, Goldberg SR. The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys. Psycopharmacology 2004; 173: 186–194
   PubMed Web of Science ®Google Scholar
• Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of Δ9-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology 2003; 169: 135–140
   PubMed Web of Science ®Google Scholar
• Justinova Z, Munzar P, Panlilio LV, Yasar S, Redhi GH, Tanda G, et al. Blockade of THC-seeking behavior and relapse in monkeys by the cannabinoid CB(1)-receptor antagonist rimonabant. Neuropsychopharmacology 2008; 33: 2870–2877
   PubMedGoogle Scholar
• Kaymakcalan S. Tolerance to and dependence on cannabis. Bulletin on Narcotics 1973; 25: 39–47
   Google Scholar
• Kaymakcalan S, Ayhan IH, Tulunay FC. Naloxone-induced or postwithdrawal abstinence signs in delta9-tetrahydrocannabinol-tolerant rats. Psychopharmacology 1977; 55: 243–249
   PubMedGoogle Scholar
• Kelly TH, Foltin RW, Emurian CS, Fischman MW. Are choice and self–administration of marijuana related to delta 9-THC content?. Experimental and Clinical Psychopharmacology 1997; 5: 74–82
   PubMedGoogle Scholar
• Kouri EM, Pope HG, Jr. Abstinence symptoms during withdrawal from chronic cannabis use. Exp Clinical Psychopharmacology 2000; 8: 483–492
   PubMed Web of Science ®Google Scholar
• Landsman RS, Burkey TH, Consroe P, Roeske WR, Yamamura HI. SR141716A is an inverse agonist at the human cannabinoid CB1 receptor. European Journal of Pharmacology 1997; 334: R1–R2
   Web of Science ®Google Scholar
• Leite JR, Carlini EA. Failure to obtain “cannabis-directed behavior” and abstinence in rats chronically treated with cannabis sativa extracts. Psychopharmacologia 1974; 8: 133–145
   Google Scholar
• Lepore M, Vorel SR, Lowinson J, Gardner EL. Conditioned place preference induced by Δ9-tetrahydrocannabinol: Comparison with cocaine, morphine, and food reward. Life Science 1995; 56: 2073–2080
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Sheikh SM, Loh HH, Martin BR. Opioid and cannabinoid modulation of precipitated withdrawal in Δ9-tetrahydrocannabinol and morphine-dependent mice. Journal of Pharmacology and Experimental Therapeutics 2001; 298: 1007–1014
   PubMed Web of Science ®Google Scholar
• Lichtman AH, Martin BR. Cannabinoid tolerance and dependence. Handbook of Experimental Pharmacology 2005; 168: 691–717
   Google Scholar
• Lile JA, Kelly TH, Hudson DA, Hays LR. Substitution profile of THC, nabilone, triazolam, hydromorphone, and methylphenidate in humans discriminating THC. 18th Annual International Cannaboinoid Research Society, Aviemore, Scotland 2008
   Google Scholar
• Mansbach RS, Nicholson KL, Martin BR, Balster RL. Failure of Δ9-tetrahydrocannabinol and CP 55,940 to maintain intravenous self-administration under a fixed-interval schedule in rhesus monkeys. Behavioral Pharmacology 1994; 5: 219–225
   PubMed Web of Science ®Google Scholar
• Mansbach RS, Rovetti CC, Winston EN, Lowe JA, III. Effects of the cannabinoid CB1 receptor antagonist SR141716A on the behavior of pigeons and rats. Psychopharmacology 1996; 124: 315–322
   PubMed Web of Science ®Google Scholar
• Martellotta MC, Cossu G, Fattore L, Gessa GL, Fratta W. Self-administration of the cannabinoid receptor agonist WIN 55,212–2 in drug-naive mice. Neuroscience 1998; 85: 327–330
   PubMed Web of Science ®Google Scholar
• McGregor IS, Issakidis CN, Prior G. Aversive effects of the synthetic cannabinoid CP 55,940 in rats. Pharmacology Biochemistry, and Behaviour 1996; 53: 657–664
   PubMed Web of Science ®Google Scholar
• McMahon LR, France CP. Discriminative stimulus effects of the cannabinoid antagonist, SR 141716A, in Δ9-tetrahydrocannabinol-treated rhesus monkeys. Experimental Clinical Psychopharmacology 2003; 11: 286–293
   PubMedGoogle Scholar
• McMahon LR. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol. Psychopharmacology 2006; 188: 306–314
   PubMedGoogle Scholar
• Mendelson JH, Mello NK. Reinforcing properties of oral Δ9-tetrahydrocannabinol, smoked marijuana, and nabilone: Influence of previous cannabis use. Psychopharmacology 1984; 83: 351–356
   PubMed Web of Science ®Google Scholar
• Mendelson JH, Mello NK, Lex BW, Bavli S. Marijuana withdrawal syndrome in a woman. American Journal of Psychiatry 1984; 141: 1289–1290
   PubMed Web of Science ®Google Scholar
• Navarro M, Chowen J, Rocío A, Carrera M, del Arco I, Villanúa MA, et al. CB1 cannabinoid receptor antagonist-induced opiate withdrawal in morphine-dependent rats. Neuroreport 1998; 9: 3397–402
   PubMedGoogle Scholar
• Navarro M, Carrera MR, Fratta W, Valverde O, Cossu G, Fattore L, et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. Journal of Neuroscience 2001; 21: 5344–5350
   PubMed Web of Science ®Google Scholar
• Nowlan R, Cohen S. Tolerance to marijuana: Heart rate and subjective ‘high'. Clinical Pharmacol Therapy 1977; 22: 550–556
   PubMed Web of Science ®Google Scholar
• Parker LA, Gillies T. THC-induced place and taste aversions in Lewis and Sprague-Dawley rats. Behavioral Newuroscience 1995; 109: 71–78
   PubMed Web of Science ®Google Scholar
• Pickens R, Thompson T, Muchow DC. Cannabis and phencyclidine self-administered by animals. Psychic dependence (Bayer-Symposium IV), L Goldfarb, F Hoffmeister. Springer, Berlin, Heidelberg, New York 1973; 78–86
   Google Scholar
• Reilly D, Didcott P, Swift W, Hall W. Long-term cannabis use: Characteristics of users in an Australian rural area. Addiction 1998; 93: 837–846
   PubMed Web of Science ®Google Scholar
• Robledo P, Berrendero F, Ozaita A, Maldonado R. Advances in the field of cannabinoid-opioid cross-talk. Addiction 2008; 13: 213–224
   Google Scholar
• Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neurospychopharmacology 2005; 30: 2035–2045
   PubMed Web of Science ®Google Scholar
• Solinas M, Panlilio LV, Justinova Z, Yasar S, Goldberg SR. Using drug-discrimination techniques to study the abuse-related effects of psychoactive drugs in rats. Nature Protocols 2006; 1: 1194–1206
   PubMed Web of Science ®Google Scholar
• Solinas M, Tanda G, Justinova Z, Wertheim CE, Yasar S, Piomelli D, et al. The endogenous cannabinoid anandamide produces δ-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. Journal of Pharmacology and Experimental Therapeutics 2007; 321: 370–380
   PubMedGoogle Scholar
• Spano MS, Fattore L, Cossu G, Deiana S, Fadda P, Fratta W. CB1 receptor agonist and heroin, but not cocaine, reinstate cannabinoid-seeking behaviour in the rat. British Journal of Pharmacology 2004; 143: 343–350
   PubMed Web of Science ®Google Scholar
• Stephens RS, Roffman RA, Curtin L. Comparison of extended versus brief treatments for marijuana use. Journal of Consulting and Clinical Psychology 2000; 68: 898–908
   PubMed Web of Science ®Google Scholar
• Tanda G, Goldberg SR. Cannabinoids: Reward, dependence, and underlying neurochemical mechanisms – A review of recent preclinical data. Psychopharmacology 2003; 169: 115–134
   PubMedGoogle Scholar
• Tanda G, Loddo P, Di Chiara G. Dependence of mesolimbic dopamine transmission on delta 9-tetrahydrocannabinol. European Journal of Pharmacology 1999; 376: 23–26
   PubMed Web of Science ®Google Scholar
• Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nature Neuroscience 2000; 3: 1073–1074
   PubMed Web of Science ®Google Scholar
• Tanda G, Pontieri FE, Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common μ1 opioid receptor mechanism. Science 1997; 276: 2048–2050
   PubMed Web of Science ®Google Scholar
• Tulunay FC, Ayhan IH, Portoghese PS, Takemori AE. Antagonism by chlornaltrexamine of some effects of delta 9-tetrahydrocannabinol in rats. European Journal of Pharmacology 1981; 70: 219–224
   PubMedGoogle Scholar
• Valjent E, Maldonado R. A behavioural model to reveal place preference to Δ9-tetrahydrocannabinol in mice. Psychopharmacology 2000; 147: 436–438
   PubMed Web of Science ®Google Scholar
• Valverde O, Maldonado R, Valjent E, Zimmer AM, Zimmer A. Cannabinoid withdrawal syndrome is reduced in pre-proenkephalin knock-out mice. Journal of Neuroscience 2000; 20: 9284–9289
   PubMed Web of Science ®Google Scholar
• Vandrey R, Budney AJ, Kamon JL, Stanger C. Cannabis withdrawal in adolescent treatment seekers. Drug & Alcohol Dependence 2005; 78: 205–210
   PubMed Web of Science ®Google Scholar
• Vlachou S, Nomikos GG, Panagis G. CB1 cannabinoid receptor agonists increase intracranial self-stimulation thresholds in the rat. Psychopharmacology 2005; 179: 498–508
   PubMedGoogle Scholar
• Wachtel SR, de Wit H. Naltrexone does not block the subjective effects of oral delta(9)-tetrahydrocannabinol in humans. Drug & Alcohol Dependence 2000; 59: 251–260
   PubMed Web of Science ®Google Scholar
• Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H. Comparison of the subjective effects of δ9-tetrahydrocannabinol and marijuana in humans. Psychopharmacology 2002; 161: 331–339
   PubMed Web of Science ®Google Scholar
• Ward AS, Comer SD, Haney M, Foltin RW, Fischman MW. The effects of a monetary alternative on marijuana self-administration. Behav Pharmacol 1997; 8: 275–286
   PubMed Web of Science ®Google Scholar
• Wiesbeck GA, Schuckit MA, Kalmijn JA, Tipp JE, Bucholz KK, Smith TL. An evaluation of the history of a marijuana withdrawal syndrome in a large population. Addiction 1996; 91: 1469–1478
   PubMed Web of Science ®Google Scholar
• Wiley JL, LaVecchia KL, Karp NE, Kulasegram S, Mahadevan A, Razdan RK, et al. A comparison of the discriminative stimulus effects of delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clinical Psychopharmacology 2004; 12: 173–179
   PubMedGoogle Scholar
• Wiley JL, Lowe JA, Balster RL, Martin BR. Antagonism of the discriminative stimulus effects of Δ9-tetrahydrocannabinol in rats and rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 1995; 75: 1–6
   Google Scholar
• Wilson DM, Varvel SA, Harloe JP, Martin BR, Lichtman AH. SR 141716 (Rimonabant) precipitates withdrawal in cannabis-dependent mice. Pharmacology Biochemistry Behavior 2006; 85: 105–113
   PubMedGoogle Scholar
• Wise RA. Addictive drugs and brain stimulation reward. Annual Review of Neuroscience 1996; 19: 319–340
   PubMed Web of Science ®Google Scholar
• Young SE, Corley RP, Stallings MC, Rhee SH, Crowley TJ, Hewitt JK. Substance use, abuse and dependence in adolescence: prevalence, symptom profiles and correlates. Drug & Alcohol Dependence 2002; 68: 309–322
   PubMed Web of Science ®Google Scholar
• Zacny JP, Chait LD. Response to marijuana as a function of potency and breathhold duration. Psychopharmacology 1991; 103: 223–226
   PubMed Web of Science ®Google Scholar
• Zangen A, Solinas M, Ikemoto S, Goldberg SR, Wise RA. Two brain sites for cannabinoid reward. Journal of Neuroscience 2006; 26: 4901–4907
   PubMed Web of Science ®Google Scholar
• Zarrindast MR, Nouri M, Ahmendi S. Cannabinoid CB1 receptors of the dorsal hippocampus are important for induction of conditioned place preference (CPP) but do not change morphine CPP. Brain Research 2007; 1163: 130–137
   PubMedGoogle Scholar